Can a targeted radiation drug delay prostate cancer progression without hormone therapy?

When prostate cancer starts to return after surgery or radiation, the standard next step is often hormone therapy, which can come with difficult side effects. A new study asked if a different treatment—a targeted radiation drug called Lu-PSMA-617—could delay that step and keep the cancer in check longer. The trial involved 58 men whose cancer was beginning to spread to a few sites. The results were striking: within the first 30 weeks, cancer progressed in only 7% of men who received the drug, compared to 93% of men who were monitored as usual. On average, the drug extended the time before the cancer worsened from 5 months to 25 months. The treatment was generally well-tolerated, with most side effects like dry mouth and fatigue being mild. However, it's important to remember this is a phase 2 trial with a small number of patients. While the results are promising and show a clear signal, we need larger studies to confirm the benefit and understand the long-term effects before this could become a standard option.